CDC Website CDC Website

To Join the NPIN community or

You are here

State Agencies

Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)

The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative on-demand, event -driven and long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy, and (HIV/STI) and non-HIV STI MPTs in cis and trans males and females of all ages.

2019 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)

The goal of the Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) program is to reduce illness and related deaths caused by a wide range of infectious disease threats. The ELC Program provides annual funding, strategic direction and technical assistance to domestic jurisdictions for core capacities in epidemiology, laboratory, and health information technology activities. In addition to strengthening core infectious disease capacities nationwide, this cooperative agreement also supports a myriad of specific infectious disease programs.

Understanding the Mechanisms of Neuropsychiatric Side Effects and Neurological Toxicities of HIV Medicines (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites innovative research grant applications focused on identifying potential mechanisms and risk factors underlying HIV treatment associated neuropsychiatric symptoms and neurological toxicities experienced by some people living with HIV infection. Exploratory and high-risk research projects that may lead to identification of targets for therapeutic interventions or personalized medicine are appropriate for this FOA. Basic and preclinical research in domestic and international settings are of interest.

STD Surveillance Network (SSuN)

In light of resurgent STDs, and a public health imperative to respond to related epidemics such as HIV and opioids, this cooperative agreement proposes new approaches to community-based enhanced and sentinel surveillance integrating monitoring of STDs, HIV and behavioral data to identify opportunities and gaps in prevention and control efforts. Systematic, ongoing collection of patient-level information to monitor the occurrence of STDs is the foundation upon which STD control programs are based.

Overdose Data to Action

The complex and changing nature of the opioid overdose epidemic highlights the need for an interdisciplinary, comprehensive, and cohesive public health approach. States, territories, and local partners need access to complete and timely data on prescribing, and on nonfatal and fatal drug overdoses to understand the scope, direction, and contours of the epidemic. They also need the tools and resources to then use data to inform and target their prevention and response efforts.

Computational Models of Immunity (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) solicits applications developing computational models of immunity that advance understanding of the mechanisms required to induce and/or maintain protective immunity to infectious pathogens, other than HIV, and/or vaccines against such pathogens. The main goal of this FOA is to advance development and application of computational models of immunity that are refined through iterative immunological experimentation to validate and improve the utility and robustness of the computational models.

Adipogenesis, Adipocyte Function and Obesity Following HIV Infection, Antiretroviral Therapy, or Pre-Exposure Prophylaxis (R01 Clinical Trial Optional)

The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that there are unique mechanisms contributing to the development of obesity in PWH versus people without HIV. Furthermore, the biology of the adipocytes might be altered in overweight or obese PWH versus overweight or obese people without HIV.

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)

NIDA is interested in research that addressing research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited.

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)

Edith Jickling's picture

NIDA is interested in research that addressing research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited.

Pages

Subscribe to RSS - State Agencies